WolverHeme Happy Hour  By  cover art

WolverHeme Happy Hour

By: Bernard Marini Anthony Perissinotti et al.
  • Summary

  • Welcome to WolverHeme Happy Hour! This is a podcast dedicated to all things hematology! We discuss new data, debate controversial therapies, and talk about new and exciting research. While we nerd out about data, we'll have a few drinks! Disclaimer: The views and opinions expressed on this podcast are solely those of the podcasters and guests and do not reflect the views or opinions of our employers or other affiliations.
    Bernard Marini, Anthony Perissinotti, et al.
    Show more Show less
Episodes
  • Anthony and Bernie get rich on no-larabine! An ASH 2023 ALL discussion
    Jan 25 2024

    In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL!


    Abstracts discussed:

    • https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions)
    • https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study
    • https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax
    • https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R T-ALL
    • https://ash.confex.com/ash/2023/webprogram/Paper187694.html - Cal-PEG is toxic
    • https://ash.confex.com/ash/2023/webprogram/Paper188064.html - Ponatinib + Blinatumomab
    • https://ash.confex.com/ash/2023/webprogram/Paper187773.html - D-ALBA (Dasatinib + Blinatumomab)
    • https://ash.confex.com/ash/2023/webprogram/Paper189632.html - GIMEMA (Dasatinib or Ponatinib + Blinatumomab)
    Show more Show less
    58 mins
  • LymphOMG: Pouring Over Lymphoma Abstracts from ASH
    Dec 29 2023

    OMG! In this extra fun holiday episode, we are joined by lymphoma experts Tycel Phillips and Aaron Goodman to review the most impactful and controversial lymphoma abstracts from ASH! Stay tuned for a lively discussion!


    Abstracts Discussed!

    1. SYMPATICO (Ibrutinib + Ven in R/R MCL): https://ash.confex.com/ash/2023/webprogram/Paper191921.html
    2. Nivo-AVD in elderly Hodgkin Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper180114.html
    3. BOVEN - Zanubrutinib + Obi + Ven in TP53 mutant MCL: https://ash.confex.com/ash/2023/webprogram/Paper180069.html
    4. CAR-T in CNS Lymphoma: https://ash.confex.com/ash/2023/webprogram/Paper174883.html (EBMT data), https://ash.confex.com/ash/2023/webprogram/Paper184345.html (Multicenter retrospective study)
    5. Synthetic Control Arms: https://ash.confex.com/ash/2023/webprogram/Paper177708.html
    6. POLARIX Subgroup Analysis (shout out to the Blood Cancer Talks crew!): https://x.com/Eddie_Cliff/status/1733901400822993257?s=20
    Show more Show less
    1 hr and 13 mins
  • AMLchemy at ASH: Brewing Success with Menin Magic, MRD Mysteries, and Aza/Ven Alchemy
    Dec 19 2023

    In this episode, Anthony and Bernie discuss the AML abstracts at ASH that we found most intriguing and controversial!

    Abstracts:

    • FILO - Stopping Aza/Ven: https://ash.confex.com/ash/2023/webprogram/Paper185437.html
    • Revumenib Late Breaking Abstract: https://ash.confex.com/ash/2023/webprogram/Paper192042.html
    • JNJ617 Menin Inhibitor Data: https://ash.confex.com/ash/2023/webprogram/Paper172422.html
    • SAVE Trial (Revumenib + PO Dec/ven): https://ash.confex.com/ash/2023/webprogram/Paper182337.html
    • Dec/Ven vs. 3+7 Randomized Phase II: https://ash.confex.com/ash/2023/webprogram/Paper181347.html
    • NCRI AML18 RCT: https://ash.confex.com/ash/2023/webprogram/Paper185956.html
    • Impact of NPM1+/FLT3+/MRD in AML17 and AML19: https://ash.confex.com/ash/2023/webprogram/Paper179033.html
    • CBF and NPM1 MRD: https://ash.confex.com/ash/2023/webprogram/Paper184848.html
    • Persistent MRD by PCR but Flow Negativity in CBF AML (Mast Cell Madness): https://ash.confex.com/ash/2023/webprogram/Paper180275.html
    • MORPHO More MRD Analysis: https://ash.confex.com/ash/2023/webprogram/Paper177929.html
    Show more Show less
    41 mins

What listeners say about WolverHeme Happy Hour

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.